| Name | Premier Home Care |
|---|---|
| Location | 823 N 4th Street, Longview, Texas |
| Certified By | Medicare |
| Services Offered | Nursing Care Physical Therapy Occupational Therapy Speech Pathology Medical Social Services Home Health Aide |
| Medicare ID | 743174 |
| Ownership Type | Proprietary |
| Service Area Zip Codes | 75455, 75480, 75494, 75568, 75571, 75601, 75602, 75603, 75604, 75605, 75607, 75630, 75631, 75633, 75638, 75640, 75642, 75644, 75645, 75647, 75650, 75651, 75652, 75654, 75656, 75657, 75659, 75661, 75662, 75663, 75668, 75670, 75671, 75672, 75683, 75684, 75685, 75686, 75691, 75692, 75693, 75702, 75707, 75708, 75755, 75762, 75765, 75783, 75792 |
| NPI Number | 1558564336 |
| Organization Name | EAST TEXAS PHC, LLC |
| Doing Business As | PREMIER HOMECARE |
| Address | 823 N 4th St, Longview, TX 75601 |
| Phone Number | 903-753-2273 |
News Archive
BerGenBio AS, an emerging oncology biopharma, today announced it has initiated preclinical development of its proprietary lead compound, BGB324. This compound will be a first-in-class inhibitor of AXL kinase.
Researchers from Tufts University School of Medicine and the Sackler School of Graduate Biomedical Sciences have identified a possible topical treatment for age-related macular degeneration in a study of mice that shows promise for clinical use.
In mice, the answer appears to be "yes," but making sure the same can happen in humans is a task that Fred Finkelman, MD, professor of medicine and pediatrics in the University of Cincinnati's (UC) College of Medicine and a researcher at Cincinnati Children's Hospital Medical Center, is attempting to tackle.
QRxPharma announced today the release of additional pivotal Phase 3 trial data for MoxDuo IR, an immediate-release Dual-Opioid pain therapy. Required for New Drug Application submission with the United States Food and Drug Administration, this "combination rule" study compared the efficacy and safety profiles of MoxDuo IR against component doses of morphine and oxycodone alone for the management of moderate to severe post-operative pain following bunionectomy surgery.
In today's headlines, reports on the latest developments related to the 'super committee's' deliberations, an appeals court issues a health law decision and results from yesterday's elections.
› Verified 9 days ago
| Quality Rating: |
News Archive
BerGenBio AS, an emerging oncology biopharma, today announced it has initiated preclinical development of its proprietary lead compound, BGB324. This compound will be a first-in-class inhibitor of AXL kinase.
Researchers from Tufts University School of Medicine and the Sackler School of Graduate Biomedical Sciences have identified a possible topical treatment for age-related macular degeneration in a study of mice that shows promise for clinical use.
In mice, the answer appears to be "yes," but making sure the same can happen in humans is a task that Fred Finkelman, MD, professor of medicine and pediatrics in the University of Cincinnati's (UC) College of Medicine and a researcher at Cincinnati Children's Hospital Medical Center, is attempting to tackle.
QRxPharma announced today the release of additional pivotal Phase 3 trial data for MoxDuo IR, an immediate-release Dual-Opioid pain therapy. Required for New Drug Application submission with the United States Food and Drug Administration, this "combination rule" study compared the efficacy and safety profiles of MoxDuo IR against component doses of morphine and oxycodone alone for the management of moderate to severe post-operative pain following bunionectomy surgery.
In today's headlines, reports on the latest developments related to the 'super committee's' deliberations, an appeals court issues a health law decision and results from yesterday's elections.
› Verified 9 days ago
| Quality Measure | Provider | National Avg. |
|---|---|---|
| How often the home health team began their patients’ care in a timely manner | 98.1 | 95.7 |
| How often the home health team taught patients (or their family caregivers) about their drugs | 96.1 | 98.6 |
| How often the home health team checked patients’ risk of falling | 100 | 99.6 |
| How often the home health team checked patients for depression | 99 | 97.4 |
| How often the home health team made sure that their patients have received a flu shot for the current flu season. | 81 | 78.7 |
| How often the home health team made sure that their patients have received a pneumococcal vaccine (pneumonia shot). | 90.4 | 82.2 |
| With diabetes, how often the home health team got doctor’s orders, gave foot care, and taught patients about foot care | 97.4 | 96.4 |
News Archive
BerGenBio AS, an emerging oncology biopharma, today announced it has initiated preclinical development of its proprietary lead compound, BGB324. This compound will be a first-in-class inhibitor of AXL kinase.
Researchers from Tufts University School of Medicine and the Sackler School of Graduate Biomedical Sciences have identified a possible topical treatment for age-related macular degeneration in a study of mice that shows promise for clinical use.
In mice, the answer appears to be "yes," but making sure the same can happen in humans is a task that Fred Finkelman, MD, professor of medicine and pediatrics in the University of Cincinnati's (UC) College of Medicine and a researcher at Cincinnati Children's Hospital Medical Center, is attempting to tackle.
QRxPharma announced today the release of additional pivotal Phase 3 trial data for MoxDuo IR, an immediate-release Dual-Opioid pain therapy. Required for New Drug Application submission with the United States Food and Drug Administration, this "combination rule" study compared the efficacy and safety profiles of MoxDuo IR against component doses of morphine and oxycodone alone for the management of moderate to severe post-operative pain following bunionectomy surgery.
In today's headlines, reports on the latest developments related to the 'super committee's' deliberations, an appeals court issues a health law decision and results from yesterday's elections.
› Verified 9 days ago
| Quality Measure | Provider | National Avg. |
|---|---|---|
| How often patients got better at walking or moving around | 67.7 | 79.6 |
| How often patients got better at getting in and out of bed | 73.3 | 81.1 |
| How often patients got better at bathing | 78.9 | 82.3 |
| How often patients’ breathing improved | 64.9 | 82.8 |
| How often patients’ wounds improved or healed after an operation | 95.9 | 92.3 |
| How often patients got better at taking their drugs correctly by mouth | 58.5 | 75 |
| How often home health patients had to be admitted to the hospital | 14.9 | 15.4 |
| How often patients receiving home health care needed urgent, unplanned care in the ER without being admitted | 15.2 | 13 |
| How often physician-recommended actions to address medication issues were completely timely | 94.6 | 94 |
News Archive
BerGenBio AS, an emerging oncology biopharma, today announced it has initiated preclinical development of its proprietary lead compound, BGB324. This compound will be a first-in-class inhibitor of AXL kinase.
Researchers from Tufts University School of Medicine and the Sackler School of Graduate Biomedical Sciences have identified a possible topical treatment for age-related macular degeneration in a study of mice that shows promise for clinical use.
In mice, the answer appears to be "yes," but making sure the same can happen in humans is a task that Fred Finkelman, MD, professor of medicine and pediatrics in the University of Cincinnati's (UC) College of Medicine and a researcher at Cincinnati Children's Hospital Medical Center, is attempting to tackle.
QRxPharma announced today the release of additional pivotal Phase 3 trial data for MoxDuo IR, an immediate-release Dual-Opioid pain therapy. Required for New Drug Application submission with the United States Food and Drug Administration, this "combination rule" study compared the efficacy and safety profiles of MoxDuo IR against component doses of morphine and oxycodone alone for the management of moderate to severe post-operative pain following bunionectomy surgery.
In today's headlines, reports on the latest developments related to the 'super committee's' deliberations, an appeals court issues a health law decision and results from yesterday's elections.
› Verified 9 days ago
| Question Type: | Rating by Patients |
|---|---|
| Health team gave care in a professional way | |
| Health team communicated well with them | |
| Health team discussed medicines, pain, and home safety | |
| How patients rated overall care from agency |
News Archive
BerGenBio AS, an emerging oncology biopharma, today announced it has initiated preclinical development of its proprietary lead compound, BGB324. This compound will be a first-in-class inhibitor of AXL kinase.
Researchers from Tufts University School of Medicine and the Sackler School of Graduate Biomedical Sciences have identified a possible topical treatment for age-related macular degeneration in a study of mice that shows promise for clinical use.
In mice, the answer appears to be "yes," but making sure the same can happen in humans is a task that Fred Finkelman, MD, professor of medicine and pediatrics in the University of Cincinnati's (UC) College of Medicine and a researcher at Cincinnati Children's Hospital Medical Center, is attempting to tackle.
QRxPharma announced today the release of additional pivotal Phase 3 trial data for MoxDuo IR, an immediate-release Dual-Opioid pain therapy. Required for New Drug Application submission with the United States Food and Drug Administration, this "combination rule" study compared the efficacy and safety profiles of MoxDuo IR against component doses of morphine and oxycodone alone for the management of moderate to severe post-operative pain following bunionectomy surgery.
In today's headlines, reports on the latest developments related to the 'super committee's' deliberations, an appeals court issues a health law decision and results from yesterday's elections.
› Verified 9 days ago
The patient survey data of Premier Home Care is compared against the national average with the color code indicators: Better than National Average Worse than National Average| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percent of patients who reported that their home health team gave care in a professional way | 92 | 88 |
| Percent of patients who reported that their home health team communicated well with them | 90 | 85 |
| Percent of patients who reported that their home health team discussed medicines, pain, and home safety with them | 87 | 83 |
| Percent of patients who gave their home health agency a rating of 9 or 10 on a scale from 0 (lowest) to 10 (highest) | 88 | 84 |
| Percent of patients who reported YES, they would definitely recommend the home health agency to friends and family | 89 | 78 |
News Archive
BerGenBio AS, an emerging oncology biopharma, today announced it has initiated preclinical development of its proprietary lead compound, BGB324. This compound will be a first-in-class inhibitor of AXL kinase.
Researchers from Tufts University School of Medicine and the Sackler School of Graduate Biomedical Sciences have identified a possible topical treatment for age-related macular degeneration in a study of mice that shows promise for clinical use.
In mice, the answer appears to be "yes," but making sure the same can happen in humans is a task that Fred Finkelman, MD, professor of medicine and pediatrics in the University of Cincinnati's (UC) College of Medicine and a researcher at Cincinnati Children's Hospital Medical Center, is attempting to tackle.
QRxPharma announced today the release of additional pivotal Phase 3 trial data for MoxDuo IR, an immediate-release Dual-Opioid pain therapy. Required for New Drug Application submission with the United States Food and Drug Administration, this "combination rule" study compared the efficacy and safety profiles of MoxDuo IR against component doses of morphine and oxycodone alone for the management of moderate to severe post-operative pain following bunionectomy surgery.
In today's headlines, reports on the latest developments related to the 'super committee's' deliberations, an appeals court issues a health law decision and results from yesterday's elections.
› Verified 9 days ago
Elite Home Health Location: 1800 Judson Road Suite 2000, Longview, Texas 75605 Ratings: Phone: (903) 212-3990 | |
Texas Home Health Skilled Services Location: 2221 H.g. Mosley Pkwy, Suite 101, Longview, Texas 75604 Ratings: NA Phone: (903) 758-0794 | |
Christus Good Shepherd Location: 103 W Loop 281 Unit 480, Longview, Texas 75605 Ratings: Phone: (903) 315-5525 | |
Encompass Home Health Of East Texas Location: 407 E Methvin St Suite 300a, Longview, Texas 75601 Ratings: NA Phone: (903) 680-2220 | |
Lifecare Health Services Location: 911 W Loop 281, Suite 204, Longview, Texas 75604 Ratings: Phone: (903) 297-9300 | |
Choice Homecare Of The Pines Location: 1125 Judson Road Suite 193, Longview, Texas 75601 Ratings: Phone: (903) 236-8880 |